Statera Biopharma Net Income vs. Gross Profit
| STABDelisted Stock | USD 0.04 0.0003 0.82% |
For Statera Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Statera Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Statera Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Statera Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Statera Biopharma over time as well as its relative position and ranking within its peers.
Statera |
Statera Biopharma Gross Profit vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Statera Biopharma's current stock value. Our valuation model uses many indicators to compare Statera Biopharma value to that of its competitors to determine the firm's financial worth. Statera Biopharma is currently regarded as top stock in net income category among its peers. It also is currently regarded as top stock in gross profit category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Statera Biopharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Statera Biopharma's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Statera Gross Profit vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Statera Biopharma |
| = | (101.88 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Statera Biopharma |
| = | 998.72 K |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Statera Gross Profit Comparison
Statera Biopharma is currently under evaluation in gross profit category among its peers.
Statera Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Statera Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Statera Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Statera Biopharma's change in net profit over the period of time. It can combine multiple indicators of Statera Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Statera Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Statera Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Statera Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Statera Biopharma's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Statera Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Use Investing Themes to Complement your Statera Biopharma position
In addition to having Statera Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Insurance Providers Thematic Idea Now
Insurance Providers
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |